Wilmer Eye Institute

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

Peter J. McDonnell, MD, reflects on his early experience managing bullous keratopathy with penetrating keratoplasty and how advances like DMEK have transformed outcomes across corneal, refractive, and cataract surgery.

Andrew G. Lee, MD, and Drew Carey, MD, discuss the case of a patient with persistent papilledema after brain tumor resection due to superficial siderosis.

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring the importance of a thorough evaluation.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how baseline optical coherence tomography parameters can help ophthalmologists counsel patients and make more informed decisions after ethambutol-associated optic neuropathy.

In cases with optic nerve hyperfluorescence or neurologic symptoms, prompt neuroimaging is warranted to rule out neuro-Behcet disease and guide multidisciplinary management.

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

An AI model for target IOP prediction performs as well as glaucoma specialists, offering a promising tool to enhance glaucoma management, especially for nonspecialists.

Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the "NeuroOp Guru" to discuss the variable presentations of somatic mitochondrial mutations and the importance of muscle biopsy in diagnosing low heteroplasmy in mitochondrial diseases.

Clinician-scientists play a vital role in advancing ophthalmology by balancing patient care with research, leveraging clinical insights to drive impactful discoveries, and collaborating across disciplines to stay at the forefront of innovation.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

As Ophthalmology Times celebrates 50 years of publication and the Wilmer Eye Institute marks 100 years of academic leadership, Peter J. McDonnell, MD, reflects on their shared commitment to helping ophthalmologists improve patient outcomes.

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that promotes blood vessel growth. Combining anti-VEGF with an experimental drug targeting HIF-1 could enhance vision outcomes and prevent vision loss.

During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr., MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.

In a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).

The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.

Cutting-edge approaches for MDs and ODs

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.

Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.

Inaugural awards honor 3 residents in ophthalmology, optometry, and retina

In this podcast, Neda Shamie, MD, and Peter J. McDonnell, MD, discuss real-world experiences, patient choices, and the nuances of integrating femtosecond laser-assisted cataract surgery into practice, offering insights into the latest developments in ophthalmology.